QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis

被引：0
|
作者：
Peyrin-Biroulet, L. [1 ]
Rubin, D. [2 ]
Lichtenstein, G. [3 ]
Shipitofsky, N. [4 ]
Huang, K. H. [4 ]
Germinaro, M. [4 ]
Wilson, R. [5 ]
Zhang, H. [5 ]
DuVall, G. A. [6 ]
Cao, Q. [7 ]
Allegretti, J. [8 ]
Feagan, B. [9 ]
Hisamatsu, T. [10 ]
Panes, J. [11 ]
Dignass, A. [12 ]
Bressler, B. [13 ]
Sands, B. [14 ]
机构：
[1] Nancy Univ Hosp, Gastroenterol, Nancy, France
[2] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA
[3] Univ Pennsylvania, Dept Med, Div Gastroenterol, Raymond & Ruth Perelman Sch, Philadelphia, PA USA
[4] Janssen Res Dev LLC, Immunol, Spring House, PA USA
[5] anssen Res Dev LLC, Biostat, Spring House, PA USA
[6] Tyler Res Inst LLC, Gastroenterol, Tyler, TX USA
[7] Zhejiang Univ, Sch Med, Hangzhou, Peoples R China
[8] Brigham & Womens Hosp, Crohns & Colitis Ctr, Gastroenterol Hepatol & Endoscopy, Boston, MA USA
[9] Alimentiv Inc, Gastroenterol, London, ON, Canada
[10] Kyorin Univ, Gastroenterol & Hepatol, Tokyo, Japan
[11] CIBERehd, Gastroenterol, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
[12] Agaples Markus Hosp, Dept Med, Frankfurt, Germany
[13] Univ British Columbia, Div Gastroenterol, Vancouver, BC, Canada
[14] Icahn Sch Med Mt Sinai, Dr Henry Janowitz Div Gastroenterol, New York, NY USA
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P493
引用
收藏
页码：624 / 625
页数：3
相关论文
共 50 条
  • [31] Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis
    Ignacio Fernandez-Blanco, J.
    Fernandez-Diaz, Guillermo
    Cara, Carlos
    Vera, Maria I.
    Olivares, David
    Taxonera, Carlos
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (03) : 731 - 737
  • [32] Adalimumab for Induction of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
    Reinisch, Walter
    Sandborn, William J.
    Hommes, Daniel W.
    D'Haens, Geert R.
    Hanauer, Stephen B.
    Schreiber, Stefan
    Panaccione, Remo
    Fedorak, Richard N.
    Tighe, Mary Beth
    Huang, Bidan
    Lazar, Andreas
    GASTROENTEROLOGY, 2010, 138 (05) : S114 - S115
  • [33] Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis
    J. Ignacio Fernández-Blanco
    Guillermo Fernández-Díaz
    Carlos Cara
    María I. Vera
    David Olivares
    Carlos Taxonera
    Digestive Diseases and Sciences, 2018, 63 : 731 - 737
  • [34] Golimumab for moderately to severely active ulcerative colitis
    Kedia, Saurabh
    Ahuja, Vineet
    Makharia, Govind K.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (10) : 1273 - 1282
  • [35] Filgotinib for moderately to severely active ulcerative colitis
    Mannucci, Alessandro
    D'Amico, Ferdinando
    El Saadi, Ahmad
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (10) : 927 - 940
  • [36] The Efficacy of Maintenance Treatment with Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase History
    Allegretti, Jessica R.
    Panes, Julian
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Yarandi, Shadi
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Zhan, Jia
    Zhang, Hongyan
    Begun, Jakob
    Kierkus, Jaroslaw
    Kravchenko, Tetiana
    Hisamatsu, Tadakazu
    Rubin, David T.
    Bressler, Brian
    Dignass, Axel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S882 - S882
  • [37] A PHASE 3 STUDY OF VEDOLIZUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN JAPANESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Watanabe, Mamoru
    Motoya, Satoshi
    Watanabe, Kenji
    Ogata, Haruhiko
    Kanai, Takanori
    Matsui, Toshiyuki
    Suzuki, Yasuo
    Shikamura, Mitsuhiro
    Igeta, Masataka
    Oda, Kazunori
    Hori, Tetsuharu
    Araki, Takahiro
    Hibi, Toshifumi
    GASTROENTEROLOGY, 2018, 154 (06) : S380 - S381
  • [38] Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials
    D'Haens, Geert
    Higgins, Peter D. R.
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Lee, Scott
    Moses, Richard E.
    Redondo, Isabel
    Escobar, Rodrigo
    Gibble, Theresa Hunter
    Keohane, Anthony
    Morris, Nathan
    Zhang, Xin
    Arora, Vipin
    Kobayashi, Taku
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (12) : 2335 - 2346
  • [39] Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
    Awni, Walid M.
    Eckert, Doerthe
    Sharma, Shringi
    Mostafa, Nael M.
    Noertersheuser, Peter A.
    Pradhan, Rajendra S.
    Robinson, Anne
    Sandborn, William
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Thakkar, Roopal
    GASTROENTEROLOGY, 2013, 144 (05) : S229 - S229
  • [40] Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis
    Kassir, Nastya
    Zhu, Rui
    Moein, Anita
    Langenhorst, Jurgen
    Ribbing, Jakob
    Zhang, Rong
    Tang, Meina T.
    Oh, Young S.
    Zhang, Wenhui
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (09): : 1234 - 1243
12345